OP-4F - Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized with Non-severe COVID-19: An Observational Analysis Emulating a Target Trial
Location: OP-04
Drug Effectiveness
Monday, Aug 23rd
5:30 PM – 6:30 PM US Eastern Time
L-1N - Comparative Effectiveness of Bevacizumab versus Cetuximab in Patients with Metastatic Colorectal Cancer
Location: L-1
Drug Effectiveness
Monday, Aug 23rd
5:30 PM – 6:30 PM US Eastern Time
L-1P - Efficacy-effectiveness Gap for Standard First-line Treatment Of
metastatic Non-small Cell Lung Cancer Among Patients with Barriers to Care
Location: L-1
Drug Effectiveness
Monday, Aug 23rd
5:30 PM – 6:30 PM US Eastern Time
L-1Q - Acute Kidney Injury in Patients with Atrial Fibrillation Treated with Rivaroxaban or Warfarin: A Population-based Study in the United Kingdom
Location: L-1
Drug Effectiveness
Monday, Aug 23rd
5:30 PM – 6:30 PM US Eastern Time
L-1R - Long-acting Insulin Analogs versus Intermediate-acting Insulin and the Risk of Major Adverse Cardiovascular Events Among Patients with Type 2 Diabetes in the United Kingdom
Location: L-1
Drug Effectiveness
Tuesday, Aug 24th
10:00 AM – 11:30 AM US Eastern Time
WS-08 - Lessons for Regulatory Decision-making from Real-world Data Trial Emulation Results
Location: WS-08
Drug Effectiveness
Tuesday, Aug 24th
1:45 PM – 3:30 PM US Eastern Time
OP-23C - Safety and Effectiveness of Prophylactic Anticoagulation for Prevention of COVID-19 Mortality: A Nationwide Cohort Study of Hospitalised Patients in the US
Location: OP-23
Drug Effectiveness
Tuesday, Aug 24th
1:45 PM – 3:30 PM US Eastern Time
OP-23D - Anticoagulants and All-cause Mortality Among Hospitalized COVID-19 Patients
Location: OP-23
Drug Effectiveness
Tuesday, Aug 24th
3:30 PM – 4:45 PM US Eastern Time
SP06A - Comparative Effectiveness and Safety of Apixaban versus Rivaroxaban Among Patients with Non-valvular Atrial Fibrillation and Liver Disease: A Population-based Cohort Study
Location: SP06
Drug Effectiveness
Tuesday, Aug 24th
3:30 PM – 4:45 PM US Eastern Time
SP06G - Best Practice Recommendations for the Design and Analyses of Pragmatic Clinical Trials: A Modified Delphi Method Study
Location: SP06
Drug Effectiveness
Tuesday, Aug 24th
5:15 PM – 6:30 PM US Eastern Time
SP10C - Oral Contraceptive Failures in the Presence of a Drug-drug Interaction – Does Progestin Type Matter?
Location: SP10
Drug Effectiveness
Wednesday, Aug 25th
11:45 AM – 1:30 PM US Eastern Time
OP-12F - Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Location: OP-12
Drug Effectiveness
Wednesday, Aug 25th
4:30 PM – 6:00 PM US Eastern Time
OP-1B - Efficacy and Safety of Treatments for Nonmetastatic Castration-resistant Prostate Cancer: A Matching-adjusted Indirect Comparison and Network Meta-analysis
Location: OP-01
Drug Effectiveness
Wednesday, Aug 25th
4:30 PM – 6:00 PM US Eastern Time
OP-11A - Calibrating Real-world Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Inflammatory Bowel Disease
Location: OP-11
Drug Effectiveness
Wednesday, Aug 25th
4:30 PM – 6:00 PM US Eastern Time
OP-11B - Shorter Drug Holiday After 3 or More Years of Risedronate versus Alendronate Is Important to Maintain Osteoporotic Fracture Protection
Location: OP-11
Drug Effectiveness
Wednesday, Aug 25th
4:30 PM – 6:00 PM US Eastern Time
OP-11C - Cardiovascular Effectiveness of SGLT-2 Inhibitors versus Metformin as First-line Treatment for Type 2 Diabetes
Location: OP-11
Drug Effectiveness
Wednesday, Aug 25th
4:30 PM – 6:00 PM US Eastern Time
OP-11D - Effect of SGLT-2 Inhibitors on Egfr in Type 2 Diabetes with Different Baseline Renal Functions: A Multi-center Study
Location: OP-11
Drug Effectiveness
Wednesday, Aug 25th
4:30 PM – 6:00 PM US Eastern Time
OP-11E - Comparative Effectiveness of Empagliflozin in Reducing Total Cardiovascular Events in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Location: OP-11
Drug Effectiveness
Wednesday, Aug 25th
4:30 PM – 6:00 PM US Eastern Time
OP-11F - Initiation of Sodium‐glucose Co‐transporter 2 Inhibitors and Progression of Renal Disease Among Patients with type-2 Diabetes: A Population-based Cohort Study
